Emergent BioSolutions signs $448 mln contract

Sept 26 (Reuters) - Emergent BioSolutions Inc (EBS.N) said it has signed a three-year contract worth $448 million with the U.S. health department, that includes delivery of anthrax vaccine, certain milestone payments and services.

The biopharmaceutical company said in a statement that it continues to expect full-year revenue growth of 10 percent to 15 percent, with a bias toward the upper end of the range, and positive net earnings. (Reporting by Deepti Chaudhary in Bangalore)